Cheng, Wenting2019-12-090142-0461http://hdl.handle.net/1885/188490China introduced dual data protection (both undisclosed information and six-year data exclusivity) for pharmaceutical products from its accession to the WTO. From 2017, a new series of policies proposed up to 12 years of data exclusivity for biologics. The drug negotiation mechanism in China should be considered in evaluating the impacts of these policies on enhanced data protectionapplication/pdfen-AU© 2019 Thomson Reuters and Contributors20182019-07-28